

# **ACL Laboratories COVID-19 and Influenza Activity Report**


Updated: Sep 19, 2021



## RESPIRATORY PATHOGEN PANEL Sep 19, 2021 Positivity Rate (%)

MONTH	FLU A Total	FLU A (H1N1)	2009 (H1N1)	FLU A (H3N2)	FLU B	RSV A	RSV B	RSV Total	PARA 1	PARA 2	PARA 3	PARA 4	Corona 229E	Corona NL63	Corona OC43	Corona HKU1	Meta pneumo	Enterovirus	ADENO	BOCA	Legionella	Chlamydia	Mycoplasma
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0	
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	0.4	0.0	0.0
AUG	0.0	0.0	0.0	0.0	0.0	0.8	12.7	13.5	0.0	1.3	6.2	0.1	0.1	0.1	0.5	0.0	0.6	14.1	1.3	3.9	0.0	0.0	0.0
SEP	0.0	0.0	0.0	0.0	0.0	0.5	7.3	7.8	0.0	0.5	1.3	0.2	0.0	0.0	0.3	0.0	0.6	12.5	0.4	2.9	0.2	0.0	0.1
OCT																							
NOV																							
DEC																							


Increased prevalence of viruses: **Rhinovirus and RSV**




ACL RSV PCR remains the same , EIA pos rate is trending down

# CDC Data RSV pos rate for Region 5 Chicago - (PCR - 21%↓, Antigen - 39% ↓)

## Total PCR Tests



## Total Antigen Tests




SARS-COV-2					Influenza - no activity				RSV (Antigen+PCR)			
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG	IL % RSVPCR	WI % RSVPCR
Sep 18	4.9	9.0	7.2	17.5	0	0	0	0	33.0	31.0	28.0	39.6
Sep 12	6.5	9.6	5.9	20.5	0	0	0	0	20.0	21.9	41.6	43.7
Sep 5	6.2	8.3	7.0	22.4	0	0	0	0	33.3	43.9	38.1	40.5
Aug 29	7.5	8.5	9.0	21.3	0	0	0	0	38.9	32.5	43.9	38.8
Aug 22	6.0	7.3	13.5	16.1	0	0	0	0	31.3	27.1	32.5	20.6
Aug 15	6.6	6.8	9.8	18.0	0	0	0	0	22.9	23.5	27.0	16.7
Aug 8	6.8	7.4	9.8	15.8	0	0	0	0	16.6	22.7	25.7	16.9
Aug 1	3.8	6.9	10.5	17.6	0	0	0	0	14.9	20.0	0.0	0.0
Jul 25	2.7	4.1	8.0	11.8	0	0	0	0	15.5	16.7	0.0	0.0
Jul 18	1.8	2.6	1.4	7.2	0	0	0	0	15.6	21.6	0.0	0.0
Jul 11	1.6	1.6	1.0	5.0	0	0	0	0	16.7	17.4	0.0	0.0
Jul 4	1.6	1.4	0.0	3.0	0	0	0	0	15.5	15.5	0.0	0.0
Jun 27	1.7	1.5	1.5	2.8	0	0	0	0	11.1	8.3	0.0	0.0
Jun 20	1.5	1.2	1.5	1.1	0	0	0	0	7.1	3.2	0.0	0.0


ACL RSV tests results are consistent with “atypical” RSV outbreak

- IL % COVAG
- WI % COVAG
- IL % SCVPCR
- WI % SCVPCR


## ACL COVAG and SCVPCR - Pos rate (%) - Sep 19, 2021



## Sep 15, 2021 - daily COVID-19 cases in US - CDC



# Sep 11, 2021 – SARS-CoV-2 circulating in the US (~99.7% Delta variants)



## US vaccination status CDC | Data as of: Sep 16, 2021

383,038,403

Vaccines Administered

210,700,361

People who received at  
least one dose

180,086,143

People who are fully  
vaccinated\*


63.5%

Percentage of the US  
population that has  
received at least one  
dose


54.2%

Percentage of the US  
population that has  
been fully vaccinated\*


## Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 27, 2020 – September 11, 2021




**2020-21 Influenza Season Week 36 ending Sep 11, 2021**



CSF targets positivity rate is 7.6%



# The most prevalent GI bacterial target is (Cryptosporidium 1.2%)



# The most prevalent GI viral target is – (Norovirus II – 0.5%)

